Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO is it bear time? Or do we go bull? | mfayman | investorshub | 09/28/2023 10:26:19 AM |
Long and strong lets hope im right | Count Crypto | investorshub | 09/28/2023 6:57:47 AM |
Price gaining | mfayman | investorshub | 09/28/2023 6:34:33 AM |
The trading last trade up | AJ Freely | investorshub | 09/28/2023 6:23:00 AM |
Price now last trade up | StocksNcash | investorshub | 09/28/2023 6:15:27 AM |
$OKYO MomentumIts now up | Sirpeter | investorshub | 09/28/2023 5:48:37 AM |
Have a look at this | Anita Dump | investorshub | 09/28/2023 12:10:48 AM |
MomentumIts now up | Count Crypto | investorshub | 09/27/2023 11:15:28 PM |
MomentumIts now up | Sirpeter | investorshub | 09/27/2023 10:08:38 PM |
$OKYO Price now | Count Crypto | investorshub | 09/27/2023 7:27:39 PM |
Do we have a winner?Turn around time? | Pisd | investorshub | 09/27/2023 5:22:21 PM |
$OKYO and the shorts continue | Count Crypto | investorshub | 09/27/2023 4:42:24 PM |
The gaining last up | mfayman | investorshub | 09/27/2023 3:31:06 PM |
MomentumIts now up | Anita Dump | investorshub | 09/27/2023 3:05:11 PM |
Good news recently, we should start to see this one move | Sirpeter | investorshub | 09/27/2023 1:11:16 PM |
$OKYO MomentumIts now last trade up | Pisd | investorshub | 09/27/2023 10:20:55 AM |
The now last trade up | Boris the Spider | investorshub | 09/27/2023 9:52:47 AM |
$OKYO The gaining | Pisd | investorshub | 09/27/2023 7:17:35 AM |
$OKYO best news of the day | Count Crypto | investorshub | 09/27/2023 7:13:58 AM |
$OKYO MomentumIts trading | Count Crypto | investorshub | 09/27/2023 7:05:39 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...